Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,514 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline 0.9% Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

NCT03429556
View directory record Official record
Conditions
Abdominoplasty
Interventions
Botulinum Neurotoxin Serotype E, Placebo
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
23 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 24, 2026, 2:29 AM EDT
Withdrawn Phase 2 Interventional

Efficacy of Acetaminophen in Posterior Fossa Surgery

NCT02532322
View directory record Official record
Conditions
Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions
IV acetaminophen, normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 24, 2026, 2:29 AM EDT
Terminated Phase 1 Interventional

Botox vs. Baclofen for Upper Limb Spasticity

NCT00280280
View directory record Official record
Conditions
Spasticity
Interventions
intramuscular Botox versus oral baclofen
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas

NCT04917861
View directory record Official record
Conditions
Zika Virus
Interventions
mRNA-1893, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
3
States / cities
Sioux City, Iowa • Lenexa, Kansas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

NCT06897202
View directory record Official record
Conditions
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
Interventions
MET097 Injection, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Bessemer, Alabama • Chula Vista, California • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 24, 2026, 2:29 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

NCT00534313
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
19
States / cities
Huntsville, Alabama • Palm Desert, California • Palo Alto, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Oct 24, 2026, 2:29 AM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

NCT05215327
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 24, 2026, 2:29 AM EDT
Recruiting Phase 2 Interventional

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

NCT07639359
View directory record Official record
Conditions
Critical Illness, Depressive Symptoms
Interventions
Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl)
Drug · Other
Lead sponsor
Hospital Italiano de Buenos Aires
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 24, 2026, 2:29 AM EDT
Withdrawn Phase 1 Interventional

Dexamethasone/Pancreatic Clamp P&F

NCT06126354
View directory record Official record
Conditions
Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions
Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 24, 2026, 2:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

NCT02063594
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NCTX (PEGylated Liposomal Iodixanol Injection), Saline Placebo
Drug
Lead sponsor
Marval Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 24, 2026, 2:29 AM EDT
Active, not recruiting Not applicable Interventional

Hypertonic Saline for Mild TBI in Pediatric Patients

NCT07060105
View directory record Official record
Conditions
Head Injury, Minor, Pediatric, Emergency Department Patient
Interventions
Hypertonic Saline ( 3% Sodium Chloride Saline), Normal Saline (0.9% NaCl)
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
8 Years to 17 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

NCT01571037
View directory record Official record
Conditions
End Stage Heart Disease, Right Ventricular Dysfunction
Interventions
inhaled nebulized milrinone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants

NCT06511973
View directory record Official record
Conditions
Pain, Healthy Volunteers
Interventions
Naproxen (BAYH006689), Placebo Gel, A solution of 0.9% Saline, A solution of 0.2% SLS
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 1 Interventional

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

NCT01134341
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions
Pralatrexate Injection, Bexarotene Capsules, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Stanford, California • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 24, 2026, 2:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

NCT04851301
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions
Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history
Behavioral · Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults

NCT02165267
View directory record Official record
Conditions
HIV Infections
Interventions
VRC01, SC placebo for VRC01, IV placebo for VRC01
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 2 Interventional Results available

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

NCT03371355
View directory record Official record
Conditions
NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions
Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 3 Interventional Results available

Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma

NCT01691508
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, OCS (prednisone/prednisolone)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Long Beach, California • Denver, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 24, 2026, 2:29 AM EDT
Terminated Phase 3 Interventional

Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery

NCT00458276
View directory record Official record
Conditions
Heart Diseases, Hypertension, Pulmonary
Interventions
tezosentan, placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Stanford, California • New York, New York • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

NCT01518985
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Bendavia, Sterile saline (0.9%), Cigarette smoking
Drug · Other
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 24, 2026, 2:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes, Youth Onset
Interventions
PI-2620 tracer
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 24, 2026, 2:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

NCT07473752
View directory record Official record
Conditions
Phase 1 First-in-human Study Involving Healthy Subjects
Interventions
TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH)
Drug · Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 24, 2026, 2:29 AM EDT
Recruiting Phase 3 Interventional

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

NCT06938347
View directory record Official record
Conditions
Right-To-Left Shunt
Interventions
Agitated Saline SoC, ASI-02
Drug
Lead sponsor
Agitated Solutions, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Chicago, Illinois • Rochester, Minnesota • Saint Cloud, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 2:29 AM EDT